Cargando…

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies

Detalles Bibliográficos
Autores principales:	Rubinstein, E, Corey, GR, Boucher, HW, Niederman, MS, Shorr, A, Torres, A, Barriere, SL, Friedland, HD
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084196/ http://dx.doi.org/10.1186/cc7474

Ejemplares similares

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Bacteremic nosocomial pneumonia cases from the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Late ventilator-associated pneumonia: analysis of baseline characteristics and clinical outcomes in the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
por: Smart, Jennifer I., et al.
Publicado: (2016)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

PNEUMONIA | Community Acquired Pneumonia, Bacterial and Other Common Pathogens
por: Niederman, M.S.
Publicado: (2006)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Severe community-acquired pneumonia
por: Niederman, Michael S., et al.
Publicado: (2022)

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials
por: Nogid, Boris, et al.
Publicado: (2018)

Community-acquired pneumonia
por: Niederman, Michael S.
Publicado: (2010)

Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
por: Barriere, Steven L, et al.
Publicado: (2014)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Adjuvant therapies in critical care: steroids in community-acquired pneumonia
por: Torres, Antoni, et al.
Publicado: (2017)

European respiratory monographs: community-acquired pneumonia
por: Niederman, Michael S
Publicado: (2014)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Too Much or Too Little Empiric Treatment for Pseudomonas aeruginosa in Community-acquired Pneumonia?
por: Torres, Antoni, et al.
Publicado: (2021)

Antimicrobial therapy of community-acquired pneumonia
por: File, Thomas M., et al.
Publicado: (2004)

Community-Acquired Pneumonia: An Unfinished Battle
por: Nair, Girish B., et al.
Publicado: (2011)

Recent Advances in Community-Acquired Pneumonia: Inpatient and Outpatient
por: Niederman, Michael S.
Publicado: (2007)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
por: Stryjewski, Martin E, et al.
Publicado: (2014)

Pneumonia: Considerations for the Critically Ill Patient
por: Niederman, Michael S.
Publicado: (2008)

Updates on community acquired pneumonia management in the ICU
por: Nair, Girish B., et al.
Publicado: (2021)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

How Does One Diagnose and Manage Severe Community-Acquired Pneumonia?
por: Brito, Veronica, et al.
Publicado: (2011)

Coagulation in hospitalized community-acquired pneumonia: disturbances in even the least ill
por: Reade, MC, et al.
Publicado: (2008)

Natural enemy or friend? Pneumonia in the very elderly critically ill patient
por: Niederman, Michael S.
Publicado: (2020)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f6lmnl09972efkkvnfvbkit7p3